Drug industry
Article Abstract:
Stocks in the pharmaceutical industry are timely in 1999 and are expected to outperform the market with good earnings growth, revenue gains from volume and other factors. However, investment trends on Wall Street, current valuations, and economic developments in Asia and elsewhere have called the industry's bull market into question. Investors need to be cautious as this sector has compression and other risks, even though its earnings are likely to remain high for several years.
Author: Rho, George, Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Schlein, Milton, Feenan, Gerard, Clark, Charles, Gallen, David, Butler, Jeremy J., Markey, Keith A., Harris, Frederick L, III, Gagas, Adam C., Owens, Victoria
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1999
Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Drugs, Dura Pharmaceuticals Inc., IDEC Pharmaceuticals Corp., DURA, IDPH
Drug industry
Article Abstract:
The pharmaceutical industry had good earnings in 1998 and profits were sharply higher, and this is expected to continue through 1999 although not at the previous pace. The stocks in this industry surged higher in 1998, also, with most of them beating the Standard and Poor's 500 index, as investors were seeking quality issues in this sector. The dynamics of these stocks are not attractive in 1999, however, even though investors can find some favorable issues.
Author: Rho, George, Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Feenan, Gerard, Harris, Frederick L., III, Clark, Charles, Gallen, David, Butler, Jeremy J., Markey, Keith A., Gagas, Adam C., Owens, Victoria
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1999
Immunetech Pharmaceuticals Inc. Dura Pharmaceuticals
Subjects list: Pharmaceutical industry, Securities, Eli Lilly and Co., Pfizer Inc., Monsanto Co., Pharmacia and Upjohn Inc., MTC, PNU, Glaxo Wellcome PLC, Genentech Inc., SmithKline Beecham PLC, Warner-Lambert Co., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Block Drug Company Inc., Chiron Corp., Covance Inc., Cygnus Inc., Forest Laboratories Inc., Genzyme Corp., Human Genome Sciences Inc., Immunex Corp., Inhale Therapeutic Systems Inc., IVAX Corp., Jones Pharma Inc., MedImmune Inc., Mylan Laboratories Inc., PAREXEL International Corp., Perrigo Co., Pharmaceutical Product Development Inc., Quintiles Transnational Corp., Schering-Plough Corp., Sicor Inc., Watson Pharmaceuticals Inc., AZA, AHP, AMGN, BRL, BGEN, BLOCA, BMY, CHIR, CVD, CYGN, FRX, GENZ, HGSI, ICN, IMNX, INHL, IVX, JMED, LLY, MEDI, MLY, PRXL, PRGO, PFE, PPDI, QTRN, SGP, SCRI, WLA, WPI, GNE, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., Agouron Pharmaceuticals Inc., AGPH, Barr Laboratories Inc., Roberts Pharmaceutical Corp., RPCX
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
